VA SB 740
Status unknownBreakthrough Therapies for Veteran Suicide Prevention Act; fund and council established, report.
Virginia · 2026 Regular Session · upper
Quick answers
Did VA SB 740 pass?
The current status of VA SB 740 is not known from the official record. Latest recorded action (2026-02-12): Continued to next session in Finance and Appropriations (15-Y 0-N)
What is VA SB 740 about?
Breakthrough Therapies for Veteran Suicide Prevention Act; fund and council established; report. Establishes the Breakthrough Therapies for Veteran Suicide Prevention Fund (the Fund) to provide funding to support clinical research and implementation of FDA Breakthrough Therapies, defined in the bill, for the treatment of post-traumatic stress disorder, treatment-resistant depression, major depressive disorder, and traumatic brain injury. Under the bill, the Fund shall be used to (i) establish public-private partnerships to jointly fund Phase III clinical trials of FDA Breakthrough Therapies; (ii) conduct investigator-initiated clinical trials; (iii) establish a compassionate use program; (iv) create education and training opportunities for mental health professionals; (v) begin patient access pilot programs; and (vi) conduct implementation studies for best practices, cost-effectiveness, and methods to reduce treatment costs. The bill also establishes the Breakthrough Therapies for Veteran Suicide Prevention Advisory Council to advise the Department of Health on administration of grant funding or contracting to carry out the purposes of the Fund. Finally, the bill requires the Board of Pharmacy to amend its regulations to designate, reschedule, or deschedule a controlled substance in accordance with federal law after the expiration of 30 days from the publication in the Federal Register of a final or interim final order or rule.
Who sponsors VA SB 740?
Michael J. Jones is the primary sponsor of VA SB 740.
Description
Breakthrough Therapies for Veteran Suicide Prevention Act; fund and council established; report. Establishes the Breakthrough Therapies for Veteran Suicide Prevention Fund (the Fund) to provide funding to support clinical research and implementation of FDA Breakthrough Therapies, defined in the bill, for the treatment of post-traumatic stress disorder, treatment-resistant depression, major depressive disorder, and traumatic brain injury. Under the bill, the Fund shall be used to (i) establish public-private partnerships to jointly fund Phase III clinical trials of FDA Breakthrough Therapies; (ii) conduct investigator-initiated clinical trials; (iii) establish a compassionate use program; (iv) create education and training opportunities for mental health professionals; (v) begin patient access pilot programs; and (vi) conduct implementation studies for best practices, cost-effectiveness, and methods to reduce treatment costs. The bill also establishes the Breakthrough Therapies for Veteran Suicide Prevention Advisory Council to advise the Department of Health on administration of grant funding or contracting to carry out the purposes of the Fund. Finally, the bill requires the Board of Pharmacy to amend its regulations to designate, reschedule, or deschedule a controlled substance in accordance with federal law after the expiration of 30 days from the publication in the Federal Register of a final or interim final order or rule.
- Introduced
- 2026-01-19
- Latest action
- 2026-02-12 — Continued to next session in Finance and Appropriations (15-Y 0-N)
- Bill type
- bill
- Last updated
- —
Sponsors
- Michael J. Jonesprimary
Committees
Not provided by source.
Action timeline
2026-01-19
Presented and ordered printed 26100205D
introduction
2026-01-19
Referred to Committee on Education and Health
referral-committee
2026-01-19
Unanimous consent to introduce
introduction
2026-02-03
Assigned Education sub: Health
referral-committee
2026-02-05
Reported from Education and Health and rereferred to Finance and Appropriations (15-Y 0-N)
committee-passage
2026-02-06
Fiscal Impact Statement from Department of Planning and Budget (SB740)
2026-02-12
Continued to next session in Finance and Appropriations (15-Y 0-N)
Versions
Documents
Votes
Reported from Education and Health
2026-02-05 · pass · 15-0
Member-level votes (15)
- Barbara A. Favola: yes
- L. Louise Lucas: yes
- Mamie E. Locke: yes
- David R. Suetterlein: yes
- Mark J. Peake: yes
- Todd E. Pillion: yes
- Jennifer B. Boysko: yes
- Lamont Bagby: yes
- Christopher T. Head: yes
- Lashrecse D. Aird: yes
- Schuyler T. VanValkenburg: yes
- Tara A. Durant: yes
- Stella G. Pekarsky: yes
- Christie New Craig: yes
- Russet Perry: yes
Continued to next session in Finance and Appropriations
2026-02-12 · pass · 15-0
Member-level votes (15)
- L. Louise Lucas: yes
- R. Creigh Deeds: yes
- Mamie E. Locke: yes
- David W. Marsden: yes
- Adam P. Ebbin: yes
- Ryan T. McDougle: yes
- Mark D. Obenshain: yes
- Richard H. Stuart: yes
- Bryce E. Reeves: yes
- Barbara A. Favola: yes
- Scott A. Surovell: yes
- Jeremy S. McPike: yes
- Jennifer B. Boysko: yes
- Todd E. Pillion: yes
- Aaron R. Rouse: yes
Related bills
No related bills recorded for this bill.
Official source
Attribution
Data from openstates_bulk_csv, retrieved 2026-07-24T05:35:59.552682Z
Inspect retained evidence for changes recorded after evidence tracking began:
Use this data
Every field on this page is available from the free public API — no key or licence required. Fetch this bill as JSON: GET /api/v1/bills?jurisdiction=VA&identifier=SB 740. See the API docs or the MCP server for AI assistants.
Known limitations
- Sponsor party and chamber affiliation are not yet captured by this API.
- Committee referrals are not yet captured.
See the methodology page for data sources and limitations.